Hanmi Pharm Co 128940.KS · KRW

Its shares trade on KRX under the ticker 128940.KS. It has been listed since 30 July 2010. In the fiscal year to 31 December 2025, it reported revenue of ₩1.55trn and net income of ₩169.55bn. At that date it held total assets of ₩2.14trn and shareholders' equity of ₩1.25trn.

Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2010-07-30. The firm operates its business through three segments. The Pharmaceuticals segment manufactures and sells tablets, capsules, injections, syrups, powders and raw materials used in the treatment of hypertension, reflux esophagitis, influenza type A and influenza type B virus infections and hyperlipidemia, among others. The Other segment is engaged in the materials processing. The Export segment produces and sells products such as powders and injections, and exports technologies.

Figures and description from our data supplier, not checked against the company's own report.

• Ms. Yeong Suk SongChairman₩1.11bn
• Mr. Jae Hyeon ParkCo-President, Chief Executive Officer, Director₩587.0m
• Mr. Jong Hun YimCo-President, Director₩522.0m
• Ms. Ju Hyeon YimVice Chairman, since 2024₩603.0m
• Mr. Yin Yeong ChoiManaging Director
• Ms. Myeong Hui ParkManaging Director
• Mr. Jung Hyeon ParkManaging Director, since 2022
• Mr. Sun Gi GwonManaging Director
• Ms. Na Yeong KimManaging Director, since 2022
• Mr. Seung Yeop LeeManaging Director
• Mr. Seong Jae ShinManaging Director
• Mr. Yeong Gil AhnAssistant Managing Director

Overall

79

Environment

99

Social

99

Governance

39

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.